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Abstract  
This report contains the updated consensus recommendations for optimal haemophilia care 
produced in 2019 by three Working Groups (WG) on behalf of European Directorate for Quality of 
Medicines & Healthcare in the frame of the Kreuth V Initiative.  
WG1 recommended the access to prophylaxis for all patients, the attainment of plasma factor 
trough levels of at least 3-5% when extended half-life FVIII and FIX products are used, treatment 
regimen personalisation and choice of chromogenic assays for treatment monitoring. It was also 
emphasized that innovative therapies should be supervised by Haemophilia Comprehensive Care 
Centres. 
WG2 recommended mandatory postmarketing data collection to assure the long-term safety and 
efficacy of new haemophilia therapies, the establishment with adequate support under public 
control of national patient registries including the core data recommended by EMA and ISTH, and 
more collaboration to facilitate comprehensive data evaluation in Europe. 
WG3 discussed methodological aspects of haemophilia care in the context of access decisions 
particularly for innovative therapies, and recommended that clinical studies should be designed to 
provide the best possible evidence needed by regulatory authorities, HTA bodies and healthcare 
providers. The dialogue between all stakeholders in haemophilia care and patient organizations 
should be fostered to implement these recommendations. 
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Introduction 
The Wildbad Kreuth Initiative started in 1999 with a seminar including experts from 15 European 
Community member states, which was followed in the next few years by a series of four meetings. 
Treatment of haemophilia has always been the focus of the initiative, given the increasing number 
of diagnosed patients and the importance of providing them with optimal therapies. Goals of the 
Initiative were to evaluate the state of haemophilia therapy, identify areas with need of further 
studies and provide updated recommendations for optimal use of blood products for patient 
treatment. The first Kreuth meeting also dealt with the optimal use of the available products in 
haemophilia therapy, emphasising that the main priority was the safety of blood and blood products 
and furthermore the need to guarantee an effective treatment, ensuring that all people with 
coagulation disorders can benefit from these lifesaving therapies.1 
The following Kreuth meetings were periodically convened under the joint auspices of the Ludwig-
Maximilian University of Munich (LMU), the Paul Ehrlich Institute (PEI) and the Council of 
Europe through its European Directorate for the Quality of Medicines & Healthcare (EDQM), under 
the aegis of the European Committee on Blood Transfusion (CD-P-TS). The latter institution 
provides resolutions that are non-binding but yet are strong indications for member states. The 
second Kreuth meeting in 2009 was attended by 110 transfusion medicine experts, haemophilia 
clinicians and regulatory authority representatives from 38 countries. New recommendations were 
provided regarding the best clinical practice on haemophilia, home treatment, genetic counselling 
and equal treatment across European member states.2 
The following two meetings in 2013 and 2016 focused on the optimal use of coagulation factors and 
provided the opportunity to review trends in the use of factor concentrates.3,4 A total of 12 
recommendations were made in 2016, dealing with national protocols or guidelines for the 
management of ageing patients with haemophilia; the minimum utilization of FVIII and FIX 
concentrates in each country; treatment for hepatitis C with direct-acting antiviral agents; genotype 
analysis for all patients with severe haemophilia; access to bypassing agents and immune tolerance 
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for those with inhibitors; individualisation of treatment regimens with extended half-life products 
and the attainment of the highest possible rate of bleeding prevention by increasing the trough 
plasma factor levels. The recommendations emerging from the 2013 and 2016 Kreuth meetings 
were subsequently incorporated by the EDQM into proposals for resolutions adopted by the 
Committee of Ministers of the Council of Europe, with the goals to increase their visibility and 
provide official weight. The 2017 Resolution [Resolution CM/Res(2017)43 on principles 
concerning haemophilia therapies]5 listed 17 principles. 
The 2019 meeting was the most recent opportunity for the official delegates nominated by 26 
Council of Europe members and observer states - along with members from the academia, the 
European Haemophilia Consortium (EHC) and the European Medicines Agency (EMA) - to review 
trends in the use of standard half-life coagulation factor concentrates but also of the new extended 
half-life products and non-replacement therapies.  
 
Methodology  
During the “Wildbad Kreuth Initiative V – Optimal Treatment of Haemophilia symposium” in June 
2019 clinicians, regulators and patient organisations from 26 European countries were involved.  
The participants are experts invited by the Scientific Programme Committee as well as delegates 
appointed by the Council of Europe (CoE) Member States upon invitation by the EDQM, plus 
delegates from the patient organizations European Haemophilia Consortium (EHC) and World 
Federation of Hemophilia (WFH) and the European Medicines Agency (EMA). Several of the 
participating experts are active members of the European Association for Haemophilia and Allied 
Disorders (EAHAD) or other scientific societies. Industry representatives had the opportunity to 
participate in the open sessions, but were excluded from the discussion and formulation of the 
recommendations. 
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The topics of the symposium were defined by the Scientific Committee on the basis of the results 
and recommendations of the previous symposia and the latest developments in the field of therapies 
for haemophilia. Subsequently, in the open plenary sessions, the invited experts presented an 
overview of the current state-of-the-art on haemophilia therapy in Europe and treatment progress on 
the topics predefined by the Scientific Committee. It was important that the chosen delegates (see 
above under 2) had not only a good scientific background but also knowledge about the peculiar 
situation of haemophilia treatment in their own countries, which was crucial to elaborate the 
recommendations to be addressed to the Health Authorities of the CoE Member States. 
The experts met in three different working groups to discuss and develop the new 
recommendations. Each working group was responsible for one of the following areas of 
discussion:   
- Clinical evaluation of haemophilia therapy; 
- Data collection for haemophilia therapy; 
- Methodological aspects of haemophilia therapy. 
An interim report was prepared by each working group, and then discussed with the general 
assembly and when full and unanimous consensus was obtained a report was presented for final 
approval. Based on the final report, this manuscript was prepared and circulated among all 
participants of the three working groups. Literature research was based on articles published in peer 
reviewed journals. Medline and PubMed were also searched for all articles published in English 
language in the last 10 years. Furthermore, data was extracted from the abstracts of the more recent 
International Congresses. 
 
Recommendation 1 
Prophylactic treatment should be available to all haemophilia patients, with or without inhibitors, 
and access to physiotherapy should be provided. 
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Prophylaxis in haemophilia is considered the standard of care to prevent joint bleeding and related 
arthropathy, with the objective to preserve a normal musculoskeletal function. Manco-Johnson 
established the superiority of prophylactic versus on-demand therapy in a randomized clinical trial 
in 2007.6 Primary prophylaxis in haemophilia should start at a very young age (≤2 years) before 
joint disease develops and usually warrants coagulation factor infusions 2–3 times per week, 
whereas secondary prophylaxis begins after the onset of joint disease.7 There are many prophylactic 
schedules, although the optimum dosing regimen remains to be defined. Prophylaxis with standard 
half-life coagulation factors products is usually given at a dose of 25–40 IU/kg 2–3 times per 
week,7,8 whereas with the extended half-life products prophylaxis regimens with intervals from 3 up 
to 5 days in haemophilia A and once every 7-14 days in haemophilia B can be effectively 
implemented.9-11 
Currently, the availability of a non-replacement therapy administered subcutaneously such as 
emicizumab makes prophylaxis accessible to all patients with haemophilia A, including those with 
FVIII inhibitors, and this may help to reduce bleeding events as well as to improve quality of 
life.12,13 
For the optimal care of haemophilia the multidisciplinary team of specialists should include 
physiotherapists. Their involvement should begin at the time of diagnosis and deal with the 
functional recovery after each musculoskeletal bleeding, but also involves a rehabilitation program 
tailored to tackle all the problems related to a chronic condition such as hemophilia.14 
 
Recommendation 2 
With increased treatment options, appropriate instruments should be developed to personalise 
treatment regimens for all patients with haemophilia A and B. 
The aim of prophylaxis is to minimize or abolish bleeding events and thus improve quality of life in 
patients. Prophylaxis regimens with standard and extended half-life products have been shown to be 
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effective at preserving joint function and preventing bleeding episodes, although a significant 
variability was seen among individuals exposed to the same treatment regimen.15 Inter- and intra-
individual variability in coagulation factor pharmacokinetics (PK) is thought to be the main 
determinant of uncertainty in the standardization of prophylaxis regimens. Appropriate tools must 
be developed to personalise treatment regimens, taking into account each patient's individual 
lifestyle and pharmacokinetic profile.16 The individualization of prophylaxis is the optimal strategy 
that could improve patients’ quality of life with the ambitious goal of zero bleeding in the next 
future. 
 
Recommendation 3 
With extended half-life therapies, a minimum trough level of 3-5% should be achieved to 
preserve joint status. 
Patients with severe haemophilia suffer from repeated and prolonged spontaneous bleeding 
episodes, mainly in muscles and joints, that result in disabling musculoskeletal damage and chronic 
arthropathy. The aim of prophylaxis in haemophilia is the reduction of the risk of bleeding in order 
to preserve a normal musculoskeletal function. Prophylaxis dosing regimens using standard half-life 
FVIII and FIX products can obtain trough plasma levels of 1-2%,17 but the introduction of extended 
half-life products significantly improves efficacy by achieving higher trough levels. A further 
improvement due to the forthcoming second-generation extended half-life products and gene 
therapies might lead to a further increase in the achievement of almost lower limits of normal factor 
levels. At the time being, with the opportunity provided by the availability of extended half-life 
products, a minimum trough level of 3-5% should be aimed in order to preserve joint function.  
 
Recommendation 4 
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For the post infusion measurement of extended half-life products chromogenic assays should be 
used.  
Haemophilia patients must be monitored by laboratory testing in order to assess the optimal plasma 
factor levels after concentrate infusion. One-stage clotting or chromogenic substrate assays have 
been used for monitoring post-infusion levels, but with the introduction of extended half-life 
products discrepancies between one-stage and chromogenic assays have been recognized. The 
choice of APTT reagents in the one-stage assays, and particularly the source of the contact 
activator, can influence assay sensitivity to the extended half-life products. This may lead to over- 
or underestimation of factor levels in patients depending on the assay used for monitoring, with the 
potential of adversely affecting management. Therefore, experts recommended as a pragmatic 
solution to switch from one-stage clotting assays to chromogenic assays.18,19 
 
Recommendation 5 
When using non-replacement therapies, for example for patients on emicizumab, some 
laboratory issues should be considered to correctly measure the procoagulant activity, FVIII 
levels after infusion of FVIII concentrate and in the estimation of FVIII inhibitors. 
Novel non-replacement therapies that decrease the effect of natural anticoagulants rather than 
replacing the deficient factor have been developed. One approach is based upon the use of a 
monoclonal antibody (concizumab) against tissue factor pathway inhibitor (TFPI), another 
emerging class is based on small interference RNA (siRNA) that reduces antithrombin expression. 
A different approach is represented by a bispecific antibody (emicizumab) that mimics the cofactor 
function of FVIII by bridging FIXa and FX. Special consideration should be given to laboratory 
monitoring in patients on the aforementioned novel approaches, especially for emicizumab, since 
this is the first non-replacement drug approved by both European and American medicine 
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regulatory agencies (EMA and FDA) for prophylaxis in adult and paediatric patients with 
haemophilia A with and without inhibitors and is currently used in clinical practice. 
Emicizumab does not affect the prothrombin and thrombin time, but tests based on intrinsic 
coagulation are affected by this drug.19,20 Conventional one-stage clotting assay overestimates the 
procoagulant activity of emicizumab, so that a modified FVIII one-stage clotting assay should be 
used to monitor this activity. The chromogenic FVIII assay is sensitive to emicizumab and provides 
an indirect measure of the procoagulant activity and drug concentration when reagents of human 
origin are used. However, there is no evidence that the procoagulant activity nor emicizumab 
concentrations are correlated with its hemostatic efficacy when assessed by the chromogenic assay 
employing human reagents. Because the measurement of plasma FVIII levels after in vitro addition 
of FVIII concentrate and the measurement of anti-FVIII inhibitor titre by the conventional Bethesda 
method employing human reagents are affected by the drug in treated patients, in order to measure 
post-infusion FVIII levels and accurately detect the inhibitor titre it is possible to employ a 
chromogenic assay but only with reagents of bovine origin that are insensitive to the presence of the 
drug.19-23 
 
Recommendation 6 
The management of patients with haemophilia, particularly those using non-replacement 
therapies and gene therapies, should be supervised by Comprehensive Care Centres, such as the 
certified European Haemophilia Comprehensive Care Centres (EHCCC). 
Haemophilia patients with and without inhibitors in Europe will be using more and more novel 
subcutaneous and innovative non-replacement therapies such as emicizumab. Haemophilia 
specialists must manage these patients in comprehensive care centres, particularly at the time of a 
major intercurrent bleeds or surgery, because the involved physicians must have adequate 
knowledge of the novel drugs and be able to handle any side effect. The need of additional 
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haemostatic drugs such as bypassing agents at the time of breakthrough bleeding and surgery may 
increase the risk of thrombosis, that must be carefully evaluated. In general, patients should be 
managed by EHCCC. The objective of these expert centres should be in the future the preparation 
and standardization of specific healthcare packages integrating comprehensive procedures for the 
management of haemophilia patients (with and without inhibitors) using emicizumab and other 
novel drugs during prophylaxis, with or without the addition of other haemostatic drugs during 
intercurrent bleeds or at the time of a surgery. The European Association for Haemophilia and 
Allied Disorders (EAHAD) and the European Haemophilia Consortium (EHC) need to update their 
joint European certification system, moving from the current self-documentation provided by each 
centre to the implementation of audit visits that are going to be the basis for decision on whether or 
not a certificate is issued.  
 
Recommendation 7 
Postmarketing data collection for the long-term safety and efficacy of all products should be 
mandatory. Every country should establish a national patient registry for haemophilia and other 
inherited bleeding disorders, covering all treatment modalities and patient-relevant outcomes. 
Since its beginning the Kreuth Initiative for optimal use of blood products has been producing 
recommendations for haemophilia treatment,4 but so far the issue of data collection was not 
addressed. Clinical registries are important tools, particularly in the context of rare diseases such as 
haemophilia characterized by a limited number of patients available for clinical trials. Registries 
may also help to collect long-term real-life data on the usage of products and patient-relevant 
treatment outcomes, thus providing valuable safety information. Registries should be set up in each 
European country on a national basis, including ideally all patients with inherited bleeding 
disorders.  
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Although recent EMA guidelines set standards for clinical studies,24 the design and conduct of the 
currently available studies are characterized by several differences which prevent comparative data 
analysis. Registries may provide relevant complementary real-life data across a variety of 
products.25 Notwithstanding the reporting obligations according to the pharmacovigilance 
legislation, registries should also collect comprehensive postmarketing safety information on all 
treatment modalities.  
 
Recommendation 8 
Dedicated data governance, evaluation and reporting should be implemented with adequate 
sustainable financial support under public control. Core data elements as recommended by 
European Medicines Agency (EMA)24,26 and minimal dataset for post-registration surveillance 
should be implemented according to the communication from the International Society on 
Thrombosis and Haemostasis (ISTH) Scientific and Standardization. Subcommittee (SSC) on 
Factor VIII, Factor IX and Rare Coagulation Disorders.27 
Although there are a number of ongoing registries in Europe, their organisation and status, as well 
as the amount and quality of collected data, is quite variable.28 There are various models of 
registries and promoters may be patient organisations, scientific societies, networks of treatment 
centres or governmental institutions. Important questions need to be answered and solutions must 
be found for each registry. How is the collection of data organised, preferably as user-friendly 
online portals? How is data integrity and quality assured? Who owns the data? Who performs which 
analysis? How and by whom are results reported and eventually published? Additional challenges 
may also be some degree of reluctance from haemophilia caregivers to share the data of their 
patients and to implement the effort needed for entering the data into a registry. To tackle these 
challenges, the German Haemophilia Register participation was recently made mandatory in 
Germany by an update of the Transfusion Act. The organisation of registries is far from being 
trivial, and needs thorough planning and substantial and sustainable support. Given the relevance of 
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the data for scientific evaluation of haemophilia treatment by regulatory agencies and the peculiar 
sensitivity of patient data, registries and their funding need to be under public control. In order to 
enable meaningful evaluation and comparative analysis, a minimum set of common data elements 
should be included, as recently recommended by EMA.26 Detailed guidance concerning the data set 
required for post-registration surveillance was also previously communicated by the ISTH 
Scientific and Standardization Committee on Factor VIII, Factor IX and Rare Coagulation 
Disorders.27 
 
Recommendation 9 
Collaboration at the European level should be encouraged, by strengthening and harmonising 
existing registries in order to facilitate pooling and comprehensive evaluation of data. 
In order to increase the amount of evaluable data and to enable pooling and a comprehensive 
evaluation of data across all treatment modalities at the European level, enhanced collaboration is 
essential. Notwithstanding the fact that the performance, cooperation and outputs of the registries 
already existing in Europe is not satisfactory,28 the way forward is not to advocate a single new, 
pan-European super-registry, but to strengthen and harmonise existing registries, as well as to 
encourage the establishment of common tools and strategies for their optimal use. This is an 
important and ambitious task which requires support by all stakeholders, including patients, 
haemophilia treaters, academia, regulatory authorities and policymakers involved in health care.  
 
Recommendation 10 
Data collection should include direct reporting from patients using appropriate electronic 
industry-independent tools. Its use should be supported by education, user-friendly applications, 
and positive feedback to the patients. 
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The ultimate success of any kind of haemophilia registry depends on the participation and 
commitment of the caregivers and the willingness of patients to provide their data. In particular, the 
accuracy and completeness of the collected data is closely related to the tools made available for 
data reporting to the registry. Data collection by direct reporting from patients through electronic 
tools is an attractive avenue provided bias due to industry-developed applications is excluded and 
supervision and quality control by the treating physicians is implemented. Of particular importance 
is the appropriate information and education about the background, instruments and goals of each 
registry, and provision of user-friendly applications. It is also important to provide patients with a 
positive feedback, with the goal to demonstrate the value of their contributions. 
 
Recommendation 11 
Clinical studies should be performed to provide the best possible evidence needed for regulatory 
authorities, health technology assessment (HTA) bodies, academia and healthcare providers. 
Clinical trials conducted during the drug licensing process provide the most important information 
for predicting the efficacy and value of new medicines. While clinical trial data are the gold-
standard of the evidence-based efficacy needed by regulatory authorities and health care providers, 
their usefulness has often limitations with respect to HTA and value determination within the frame 
of cost-effectiveness studies, primarily done in the interest of the decision-making processes of 
payers. The purpose of most clinical trials is to test hypotheses about the efficacy and side effects of 
medications, compared against placebo or a selected comparator therapy. HTA aims at answering 
questions about how these findings can be translated into clinical practice and change the standard 
of care, but also on how to estimate cost-effectiveness, with the goal to inform decisions intended to 
ensure value for money. Most clinical trials often do not focus on endpoints such as the patient 
relevant outcomes requested by HTA bodies and/or payers. These limitations have become more 
relevant after regulatory authorities introduced new initiatives such as adaptive licensing in order to 
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accelerate access to innovative treatments, particularly in the context of orphan or rare diseases. 
Smaller and shorter trials may be able to provide faster evidence, but they will fail to generate 
enough information for patient assessment of relevant outcomes and for cost-effectiveness. To 
minimise these gaps of knowledge and provide sufficient evidence in order to optimize usefulness 
for HTA and cost effectiveness analysis, clinical trial designs for innovative therapies should be 
optimised to reduce uncertainty, eliminate bias, decrease costs and accelerate patient access. 
 
Recommendation 12 
A process to reach better agreement on relevant indicators and methods should be started in 
order to meet the needs of regulatory authorities, HTA bodies, academia and healthcare 
providers, that have different foci, responsibilities and requirements. 
There is a strong need for a multidisciplinary consensus on measurable, patient-relevant outcome 
indicators which reflect the benefits of new and innovative haemophilia therapies. Consensus on the 
choice of outcome assessment instruments should also be reached in order to allow for a more 
effective combination of data from different sources. These goals will be necessary to obtain 
harmonized and transparent decision-making processes. It should also be discussed if outcomes 
should be collected in clinical trials or if data from other sources such as observational studies 
including registries should be complementary sources for benefit assessment in haemophilia care. 
Furthermore, a minimum set of methods for outcome determination would be helpful for benefit 
assessment by the different decision makers. Because haemophilia is a chronic rare disease and hard 
patient-relevant outcomes like avoidance of joint damage cannot be evaluated at the time of market 
entry of innovative therapies, it is important to identify appropriate surrogate indicators and agree 
on statistical methods for prognostic calculations, in order to provide estimates also on medium to 
long-term consequences.  
 
Recommendation 13 
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A dialogue with agencies and academia should be started in order to reach understanding of 
relevant outcomes and to ensure comprehensive and consistent reporting. 
HTA bodies and/or payers request information on patient-relevant clinical endpoints in order to 
provide the evidence of therapeutic benefit of new or innovative therapies compared to the standard 
of care. These hard endpoints are mainly morbidity, mortality and quality of life, but these reflect 
only partially the benefits associated with innovative haemophilia therapies.29 Even though 
mortality in haemophilia was very high before the introduction of replacement therapy, nowadays it 
is almost comparable to that of the general population, so that it cannot be seen as an appropriate 
outcome to be measured at the time of drug evaluation and market entry. Repeated joint bleeds 
cause morphological changes and lead to arthropathy on the long run, but many years of follow-up 
would be required to assess hemophilic arthropathy and its consequences. Multifactorial influences 
lead to individual variations in a small patient population such as haemophilia pertaining to the 
bleeding phenotype, development of arthropathy and inhibitory antibodies. Thus, the measurement 
of health-related quality of life (HRQoL) might be a reasonable indicator of the long-term outcome 
and effectiveness of the therapeutic intervention chosen. It can also be converted into utility values 
to enable the assessment of gained quality-adjusted life years (QALYs), and to calculate cost-
effectiveness. Both hemophilia disease-specific instruments and generic instruments are available 
and should be implemented as a standard procedure.  
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